quinazolines has been researched along with Nail Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianca, D; Caro, G; Fabbrocini, G; Panariello, L | 1 |
| Aractingi, S; Nassar, D; Soutou, B | 1 |
| How, CK; Huang, MS; Su, PH; Yen, DH | 1 |
| Garden, BC; Lacouture, ME; Wu, S | 1 |
| Dainichi, T; Furue, M; Noda, K; Tanaka, M; Tsuruta, N | 1 |
| High, WA | 1 |
| Lacouture, ME; Mitchell, EP; Perez-Soler, R; Van Cutsem, E | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
3 review(s) available for quinazolines and Nail Diseases
| Article | Year |
|---|---|
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Incidence; Lapatinib; Nail Diseases; Nails; Panitumumab; Quinazolines; Risk Factors | 2012 |
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Lapatinib; Nail Diseases; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Telangiectasis | 2007 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
5 other study(ies) available for quinazolines and Nail Diseases
| Article | Year |
|---|---|
Phenol 8% solution for the treatment of epidermal growth factor receptor inhibitor-induced periungual pyogenic granulomas.
Topics: Administration, Topical; Antineoplastic Agents; Breast Neoplasms; Caustics; Cautery; ErbB Receptors; Female; Granuloma, Pyogenic; Humans; Lapatinib; Middle Aged; Nail Diseases; Neoplasm Proteins; Phenol; Protein Kinase Inhibitors; Quinazolines; Toes | 2015 |
[Cutaneous side effects of EGF receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gefitinib; Humans; Nail Diseases; Panitumumab; Quinazolines; Skin | 2009 |
Melanonychia secondary to hydroxyurea.
Topics: Aged; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hyperpigmentation; Nail Diseases; Platelet Aggregation Inhibitors; Plateletpheresis; Quinazolines; Risk Factors | 2012 |
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Nail Diseases; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index | 2003 |
Gefitinib: a cause of pyogenic granulomalike lesions of the nail.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Gefitinib; Granuloma, Pyogenic; Humans; Lung Neoplasms; Nail Diseases; Quinazolines | 2006 |